Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
66.6 GBX | -1.48% | +3.10% | -0.60% |
04/04 | NIOX Group Plc Proposes Final Dividend for the Financial Year Ended 31 December 2023, Payable on 24 June 2024 | CI |
26/03 | EARNINGS: CAB Payments profit drops, Life Science REIT cuts dividend | AN |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-0.60% | 352M | C+ | ||
+25.83% | 661B | C+ | ||
+27.00% | 566B | B | ||
-6.76% | 352B | C+ | ||
+20.34% | 332B | B- | ||
+3.00% | 283B | C+ | ||
+13.09% | 231B | B+ | ||
+5.46% | 200B | B- | ||
-9.61% | 195B | A+ | ||
-6.26% | 145B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CIR Stock
- Ratings NIOX Group Plc